Chemical and Biological Aspects of Nutritional Immunity-Perspectives for New Anti-Infectives that Target Iron Uptake Systems by S. Laschat et al.
This is a repository copy of Chemical and Biological Aspects of Nutritional Immunity - 
Perspectives for New Anti-infectives Targeting Iron Uptake Systems : Perspectives for 
New Anti-infectives Targeting Iron Uptake Systems.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/119363/
Version: Accepted Version
Article:
Bilitewski, Ursula, Blodgett, Joshua A.V., Duhme-Klair, Anne Kathrin 
orcid.org/0000-0001-6214-2459 et al. (4 more authors) (2017) Chemical and Biological 
Aspects of Nutritional Immunity - Perspectives for New Anti-infectives Targeting Iron 
Uptake Systems : Perspectives for New Anti-infectives Targeting Iron Uptake Systems. 
Angewandte Chemie International Edition. pp. 2-25. ISSN 1433-7851 
https://doi.org/10.1002/anie.201701586
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Angewandte
International Edition
A Journal of the Gesellschaft Deutscher Chemiker
www.angewandte.org
Chemie
Accepted Article
	
 	
		

			

			
		 !
"

 "#	$
% 		!	%&%
'	('	%"#	(%)%
)	"
#
	
	#

	


	
				%	%#	
	
	*	)
+*),-	!	

	##
	(		.#/
		+(.,	#-*)	#
#			0*		##	
 	

	
 		-)#	
 *)   / #	  #  	 	 #	



		-	#

	

	
-
		
 	



12-12234	-321521678
	

12-12234-321521678

 944:-	-412-12234	-321521678
944:-	-412-12234-321521678
Chemical and Biological Aspects of Nutritional Immunity ± Perspectives for 
New Anti-infectives Targeting Iron Uptake Systems 
10.1002/anie.201701586Angewandte Chemie International Edition
This article is protected by copyright. All rights reserved.
2 
 
Chemical and Biological Aspects of Nutritional Immunity ± Perspectives for 
New Anti-infectives Targeting Iron Uptake Systems 
Ursula Bilitewski,* Joshua A. V. Blodgett, Anne-Kathrin Duhme-Klair, Sabrina Dallavalle, 
Sabine Laschat, Anne Routledge, and Rainer Schobert 
 
Dedicated to Prof. Gerhard Erker on the occasion of his 70th birthday. 
 
Upon bacterial infection one of the defense mechanisms of the host is the withdrawal of 
HVVHQWLDOPHWDO LRQV LQSDUWLFXODU LURQ OHDGLQJ WR³QXWULWLRQDO LPPXQLW\´+RZHYHUEDFWHULD
have evolved strategies to overcome iron starvation, e.g. by stealing iron from the host or 
other bacteria by specific iron chelators with high binding affinity. Fortunately, these complex 
interactions between host and pathogen regarding metal homeostasis provide several 
opportunities for interception and thus allow the development of novel antibacterials. The 
current review will give an overview with a major focus on iron, discuss recent highlights and 
will give some future perspectives, which are relevant in the fight against antibiotic resistance.  
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1. Introduction 
As recently emphasized by the WHO[1] DQGWKH3(:&KDULWDEOH7UXVWLQWKHLU³6FLHQWLILF
5RDGPDS IRU$QWLELRWLF 'LVFRYHU\´[2] the development of novel strategies to fight bacterial 
infections is one of the most urgent goals for preserving public health. This is mainly due to 
the increasing number of bacterial strains which are resistant to a wide spectrum of 
antibiotics.[3] On the other hand many pharmaceutical companies worldwide have almost 
abandoned the development of novel anti-infectives.[4] Among the current research efforts the 
activities exploiting host±pathogen±interactions and aiming at strengthening the host immune 
system are particularly promising. 
Infections are established when pathogens grow, proliferate or replicate within a host without 
limit. This is true for all types of pathogens, but in this article we focus our discussion on 
pathogenic bacteria. 
A prerequisite for unlimited proliferation of bacteria is the adequate supply with 
nutrients. Thus, the first line of defense of the host against infections is the withdrawal of 
nutrLHQWV IURP WKH SDWKRJHQ D SKHQRPHQRQ FDOOHG ³QXWULWLRQDO LPPXQLW\´ :KHUHDV
pathogens can adapt central metabolic pathways to the respective available carbon and 
nitrogen sources, hosts have developed efficient means to limit the availability of essential 
metal ions. This is reflected in in vivo transcriptomic studies of bacteria from infection sites of 
animal models showing a stress response to metal ion limitation.[5±7] The best studied example 
is the dependence of pathogens on iron[8] so that most research approaches aiming at the 
exploitation of nutritional immunity as therapeutic target address the iron acquisition systems. 
That is why in the current review mainly iron acquisition systems and respective chemical 
inhibitors are described, but where possible we also include chemical approaches to influence 
the uptake of other metal ions. For various other aspects related to nutritional immunity, the 
recent reviews on microbiological aspects,[9,10] coordination chemistry of siderophores,[11] 
environmental applications of siderophores,[12] zinc homeostasis[9,13] and chemical synthesis 
of antibacterials[14] are highly recommended. More specific reviews can be found in the 
following chapters. 
2. Iron Acquisition, one Aspect of Nutritional Immunity and of Host-Pathogen 
Interactions  
Almost all organisms depend on iron due to its favorable properties as redox and as 
complexing agent. Thus, iron ions are present as different species and the Fe2+/3+ redox couple 
is involved in electron transfer reactions of the energy metabolism, but also in stabilizing 
protein structures and transportation of oxygen. In response to the iron - deficient situation in 
the host bacteria have developed various iron uptake systems[8] which are specific for the 
available iron species (Figure 1). 
Within a vertebrate host the most abundant iron species is heme (approximately 70% of 
the total iron). Heme is a cofactor of intracellular proteins, for example catalyzing electron 
transfer reactions in cytochromes and peroxidases or allowing oxygen transport by 
hemoglobin. Thus heme can be used as an iron source only by intracellular pathogens or by 
pathogens, which produce cytolysins or hemolysins to disrupt host cells and lead to the 
release of hemeproteins. Though heme is essential also for host cells, free heme becomes 
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highly cytotoxic due to its redox properties, which induce oxidative stress. Thus, hemoglobin, 
present in the blood after release from damaged erythrocytes, is rapidly complexed by 
protective proteins, such as haptoglobin, and cleared mostly via the liver and the spleen.  
 
Figure 1. Bacterial iron uptake systems for different iron species, redrawn from Ref. [15]. ABC transporters 
comprise a permease and an ATP-binding cassette protein. Membrane-bound siderophore receptors (Gram-
positive: green symbol, Gram-negative: blue symbol) are for example HtsA of S. aureus and FepA from E. coli. 
Periplasmic binding proteins (E. coli) are FepB and FhuD and FepCDG and FhuCB are among the ABC 
transporter complexes. Heme uptake by Gram-negative bacteria (violet symbol; example: Phu system of P. 
aeruginosa) follows a similar principle as siderophore uptake. However, siderophores are recycled, whereas 
heme is degraded by oxygenases. Heme / hemoglobin receptors of Gram-positive bacteria are attached to the 
peptidoglycan layer (not inserted in the cytoplasmic membrane). Examples are IsdH and IsdB of S. aureus, with 
the heme binding protein IsdC transporting the heme through the peptidoglycan layer. The ABC complex for 
heme transportation of S. aureus is the IsdDEF±complex. 
Tf: Transferrin, Lf: Lactoferrin, Tbp/Lbp: Transferrin/Lactoferrin binding protein; the TonB/ExbB/ExbD 
complex delivers the energy for the transport of siderophores and of heme through the outer membrane. 
To get access to heme iron bacteria have developed various sophisticated protein systems, 
which can be classified into direct and hemophore-mediated heme uptake systems. Examples 
for direct heme uptake systems are the Phu system (Pseudomonas heme uptake) and the isd 
system (iron-regulated surface determinant) from Pseudomonas aeruginosa and 
Staphylococcus aureus, respectively. They comprise cell surface receptors, which bind 
hemoglobin-haptoglobin complexes or hemoglobin (e.g. IsdH and IsdB), extract heme from 
these proteins and transfer it to ATPase transporter complex (e.g. IsdDEF). The second heme 
acquisition system relies on hemophores (not shown in Figure 1). These are bacterial secreted 
proteins, e.g. the HasA (heme acquisition system) from Serratia marcescens, which bind free 
heme or extract it from hemeproteins and shuttle it to the cell surface, where the complex is 
bound by hemophore specific receptors, e.g. HasR. From the receptors heme is transported 
through the cell membranes and the periplasm to the cytosol, where heme is degraded by 
oxygenases and Fe2+ is extracted. Hemophore-transport through the outer membrane of Gram-
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negative bacteria is an energy consuming step, which is enabled by coupling to the membrane 
potential of the inner membrane via the transperiplasmic protein TonB and the proteins of the 
inner membrane ExbB and ExbD, similar to the transport of siderophores (see below) (Figure 
1). Direct heme transport through the periplasm and the peptidoglycan layer respectively 
occurs via binding proteins, e.g. PhuT and IsdC. Usually expression of these protein systems 
is regulated in response to iron limitation via the Fur (ferric uptake regulator) repressor. 
Extracellular iron would be more easily accessible to invading bacteria. However, due to the 
aerobic conditions in body fluids (serum, tears, sweat) extracellular iron usually is present as 
Fe3+ and is predominantly complexed by transport proteins, such as transferrin (Tf) and 
lactoferrin (Lf).[16] These high-affinity protein complexes contribute to the iron-limited 
environment experienced by bacteria invading a host. Pathogens have developed different 
systems to get access also to these iron species: bacteria from the Neisseriaceae and 
Pasteuellaceae families bind the iron-loaded host proteins via surface receptors, extract the 
Fe3+-ions and channel them through the bacterial cell membranes.[17,18]  
More common, however, are low-molecular weight Fe3+-chelating compounds (typically <1 
kDa), the siderophores, which are secreted by microorganisms and steal Fe3+ from the host 
proteins due to higher affinities. To date more than 250 different siderophores are structurally 
characterized and grouped according to the functional groups which are involved in Fe3+-
coordination. The most common motifs are catecholates, hydroxamates, Į-
hydroxycarboxylates and phenolates (examples are shown in Figures 3±5), which can also be 
FRPELQHGLQ³PL[HGW\SH´VLGHURSKRUHV.[19] Binding constants for Fe3+ vary over more than 30 
orders of magnitude. As only deprotonated donor atoms (O and N) are effective, binding 
constants are dependent on pH and the competitive advantages of the different siderophore 
types depends on the body niche and its physico-chemical properties.  
 
Figure 2. Control of gene expression via IdeR by Fe2+ concentration. In the presence of high iron concentrations 
in Mycobacterium tuberculosis biosynthesis of siderophores is repressed, as the transcriptional regulator IdeR 
(iron dependent regulator) is complexed with iron. This IdeR-Fe±complex is bound to DNA and represses 
expression of genes, which have a Fe-box in their promoter regions, such as the mbt gene clusters for the 
synthesis of the siderophore mycobactin (see also Fig. 3). Under low iron conditions iron dissociates from the 
IdeR-Fe±complex, which induces the relief of the repression and induces expression of the respective genes 
(redrawn from Ref. [21]). 
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Biosynthesis of siderophores is regulated via intracellular iron concentrations following the 
principle of induced gene expression under low intracellular iron concentrations, as shown for 
Mycobacterium tuberculosis in Figure 2. Other bacteria use the Fur transcriptional regulator 
instead of IdeR (iron dependent regulator). A comprehensive description of Fur regulation can 
be found in a recent review.[20] 
Two different synthesis principles are known, either via the protein complexes of non-
ribosomal peptide synthetases (NRPS) (Figure 3) or via NRPS-independent siderophore (NIS) 
synthesis. NRPS incorporate aryl and amino acid building blocks, whereas NIS synthesis is 
based on amide or ester bond formation between dicarboxylic acids, diamines, amino alcohols 
or alcohols. Siderophore biosynthetic pathways have been reviewed by Challis.[22] 
 
Figure 3. NRPS-dependent siderophore biosynthesis showing the pathways for example to the phenolate 
siderophores yersiniabactin 1, pyochelin 2 and mycobactin 3 (see chapter 3.2.) and the catecholate siderophore 
enterochelin 4. EC: 5.4.4.2 Isochorismate synthase; 3.3.2.1 bifunctional isochorismate lyase/acyl carrier protein; 
4.2.99.21 isochorismate pyruvate lyase; 1.3.1.28 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase; 6.3.2.14 
enterobactin synthase; Source: KEGG-database. 
After synthesis, siderophores are secreted from the cell via export systems and get loaded with 
Fe3+ in the extracellular space.[23] Fe3+-loaded siderophores are bound by specific cell-surface 
receptors, e.g. HtsA from Staphylococcus aureus binds the carboxylate siderophore 
staphyloferrin A, FepA from E. coli the catecholate siderophore enterochelin 4. In Gram-
negative bacteria internalization into the cytoplasm is achieved via energy-consuming TonB-
dependent transport through the outer membrane (Figure 1), shuttling by periplasmic binding 
proteins, e.g. FepB from E. coli, and transportation into the cytosol via ATPases, e.g. 
FepCDG. In the cytosol Fe3+ is extracted from the siderophore and is reduced to Fe2+ (Figure 
1). 
In response to secretion of the siderophore enterochelin 4, nowadays better known as 
enterobactin (Ent), by Gram-negative bacteria, neutrophils and host mucosal cells secrete the 
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Ent±binding protein lipocalin 2 (Lcn2), thus disrupting the bacterial iron acquisition system 
by neutralizing the siderophores and preventing their re-uptake by the bacteria. As a 
countermeasure pathogens produce alternative siderophores, which are not bound by lipocalin 
2, for example yersiniabactin 1 or glycosylated Ent, also called salmochelin.[24]  
Thus, bacteria possess several, at least partly redundant iron acquisition systems, which allow 
adaptation to different environmental niches according to the respective available iron source. 
As pathogens are highly dependent on iron acquisition, these systems are attractive targets for 
therapeutic intervention or vaccination strategies. Due to its almost universal presence the 
siderophore biosynthesis and uptake systems are most frequently targeted either by inhibitors 
or by siderophore±antibiotic conjugates, so-cDOOHG ³7URMDQ KRUVHV´ ZKLFh utilize the 
siderophore transport proteins to facilitate transportation of antibiotics into the cells.[25] 
However, some pathogens, such as Staphylococcus aureus rely on heme utilization and 
inhibition of the access to intracellular heme proteins could also be a valuable therapeutic 
target.[26,27] 
3. Inhibition of the Acquisition of Extracellular Iron 
3.1. Regulation of Iron Uptake Systems 
As iron is an essential but in too high concentrations also a toxic metal ion, its uptake is 
carefully regulated by the availability of Fe2+/3+. Thus, only when intracellular Fe2+ 
concentrations are low, the genes for siderophore biosynthesis, siderophore or heme receptors 
and binding proteins are expressed. This regulation is largely dependent on DNA binding 
proteins, such as Fur and IdeR (Figure 2), which bind Fe2+, but also Fe3+ and other divalent 
metal ions, such as Zn2+, Mn2+ or Co2+. Metal binding increases the stability of a Fur±dimer 
and the affinity of Fur to its DNA binding site, which represses expression of genes involved 
in iron uptake. Decreasing intracellular metal ion concentrations leads to dissociation of the 
metal ion from the protein and as a consequence to the dissociation of the protein from the 
DNA, and thus to the induction of gene expression. It is expected that any interference with 
this regulatory system will affect bacterial viability and physiology, as inhibition of DNA 
binding will lead to uncontrolled uptake of Fe2+/3+ and thus to the toxic effects from high Fe2+ 
concentrations, and activation of DNA binding even in the absence of Fe2+ will further 
decrease intracellular Fe2+ concentrations. 
Inhibition of IdeR binding to DNA was already described in 2007 by Monfelli and Beeson.[28] 
They claimed that they had identified small peptides, which modulated IdeR activity. 
However, no peptide sequences were given. This approach was followed by Michaud-Soret 
and Crouzy,[29] who identified peptide aptamers, which inhibited the activity of Fur in the µM 
range. However, these peptides were tested only in cell-free in vitro systems so that the final 
proof of concept is still pending.  
Klemm made use of the higher affinity of Fur for Zn2+ and Co2+ and added 500 µM Zn2+ to 
the medium during biofilm formation by Escherichia coli and Klebsiella pneumoniae under 
nonlimiting iron conditions.[30] They observed significantly reduced biofilm formation in 
microtiter plates and also on urinary catheters, which they took as a proof that iron uptake is 
important for biofilm formation and that interference with these uptake systems may be an 
effective way to eradicate biofilms from pathogenic strains. 
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Zn2+ also is an essential trace element, which is toxic at high concentrations, requiring 
regulated uptake systems, as described for Fe2+. Indeed, high-affinity uptake systems are 
described for example for the Gram-negative bacteria Escherichia coli[31a] and Acinetobacter 
baumanii,[31b] the expression of which is regulated by the DNA-binding protein Zur (zinc 
uptake regulator), which has high homology to the iron uptake regulator Fur and whose 
activity is also dependent on dimerization. However, until now no chemical inhibitors of Zur 
activity are described. 
3.2. Biosynthesis of Siderophores 
Under aerobic conditions iron usually exists in the Fe3+ oxidation state. Due to its low 
solubility, this form is hardly bioavailable, which has led to the evolution of biosynthetic 
pathways for small molecules with high binding affinity for Fe3+ called siderophores. Such 
molecules are broadly employed by microbes for iron acquisition, including pathogens and 
non-pathogens. 
For environmental microorganisms the ability to block neighboring strains from producing 
siderophores, thus restricting critical iron uptake, is a competitive advantage. Screens to 
discover such inhibitors of two pathogen associated NIS biosynthetic enzymes[32] led to the 
discovery of baulamycin A & B 5a,b. Baulamycin A (5a) is the most active of the pair, 
inhibiting AsbA and SbnE with IC50 values at 180 µM and 4.8 µM, respectively (Figure 4). 
These enzymes conjugate spermidine 9 or L-2,3-diaminopropionic acid 10 with citrate 8 in an 
ATP dependent fashion during staphyloferrin 6 and petrobactin 7 siderophore biosynthesis. 
 
Figure 4. A) Baulamycin A 5a, a natural product discovered in screens for staphyloferrin and petrobactin-family 
siderophore inhibitors. B) Baulamycins inhibit the AsbA-catalyzed condensations of citrate 8 with sperimidine 9 
in petrobactin 7 biosynthesis, and the analogous SbnE-catalyzed condensation of 8 and diaminopropionic acid 10 
in staphyloferrin 6 biosynthesis. 
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These siderophores are important for Bacillus anthracis and Staphylococcus aureus 
virulence,[33] and baulamycins 5 are antibacterial when assayed against these bacteria. 
However, 5a causes growth inhibition under both iron-limiting and iron-replete conditions at 
similar concentrations, suggesting the antibiosis of these compounds unlikely stems from 
siderophore inhibition alone. Despite the uncertainty surrounding baulamycin targets in vivo, 
5 rank among the only natural siderophore biosynthetic inhibitors discovered thus far. 
Molecules that act analogously to the baulamycins 5, but inhibit other siderophore 
biosynthesis pathways likely exist in nature. 
The knowledge of siderophore biosynthesis also provides the opportunity for targeted design 
of synthetic small molecule inhibitors which have the overall effect of withholding essential 
iron from the microorganism, inducing nutritional immunity. A comprehensive overview of 
siderophore biosynthesis inhibitors was recently published.[34] Thus, we focus on a survey of 
current research (2015/2016); the majority of the work in this period has been targeting 
siderophore biosynthetic pathways of Mycobacterium tuberculosis, the causing agent of 
tuberculosis, specifically adenylation inhibitors. Although this target was covered in the Lamb 
review our review focuses on the most recent work in the area. Two publications in the period 
VXUYH\HGLQKLELWRUVWKDWWDUJHWRWKHUVLGHURSKRUHELRV\QWKHWLFSDWKZD\V7DQ¶VD-hydroxyacyl-
DGHQRVLQH¶-O-monosulfamate derivatives to probe inhibition of HMWP2 via inhibition of 
the cysteine adenylation domain and subsequent yersiniabactin 1 production.[35] .LULHQNR¶V
use of 5-fluorouridine to inhibit pyoverdine biosynthesis in P. aeruginosa[36] via RNA 
disruption are included here for completeness. 
M. tuberculosis is exposed to the iron-limited intracellular environment of macrophages 
during host infection. Intracellular survival of the bacteria depends on the production of 
mycobactin-class siderophores 3 (e.g. 3a, Figure 5) PDNLQJ WKH SDWKRJHQ¶V LURQ XSWDNH
system an attractive target for therapeutic intervention. 
 
Figure 5. Biosynthesis of 5'-adenosyl salicylate 16, a precursor of the siderophores 1 and 3. 
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Mycobactins 3 have salicylic acid 15 as a structural substituent, which is also common to a 
number of other pathogen siderophores, including yersiniabactin 1, produced by Gram-
negative Yersinia sp.. Siderophores containing 15 are particularly suitable for drug design 
because 15 is an important metabolite in some plants and bacteria, while humans do not 
produce the compound minimizing toxicity risk after dosing. 
In M. tuberculosis, 15 is elaborated from the central metabolite chorismate 13 by MtbI, a 
salicylate synthase that acts via an isochorismate 14 intermediate. After MbtI produces 15, it 
is activated for NRPS incorporation in a reaction catalysed by MbtA, a representative of the 
aryl acid adenylating enzymes (AAAE). These enzymes are present in a number of 
pathogenic bacteria and are essential for NRPS±dependent siderophore biosynthesis.[37] The 
reaction requires ATP and releases inorganic pyrophosphate and the salicyl adenylate 16, 
which is subsequently loaded on the NRPS assembly line finally leading to 3. MbtI and MbtA 
have been targeted with biosynthetic intermediate analogs, as noted below. 
7KH QXFOHRVLGH DQWLELRWLF ¶-O-[N-(salicyl)sulfamoyl]adenosine (SAL-AMS 17) is a 
prototype for a new class of antibiotics that inhibit AAAE.[37,38] Numerous analogs have been 
synthesized (covered in the Lamb review)[34] but more recently, Aldrich synthesizHG¶- and 
¶-fluorine analogs of a sulfamide isostere 18[39] ZLWKWKHVXJDUVDGRSWLQJWKHQRUWKHUQ&¶-
endo&¶-exoRUVRXWKHUQ&¶-endo&¶-exo) pucker (Figure 6). 
 
Figure 6. Structure of nucleoside antibiotic SAL-AMS 17 and modified derivatives 18. 
The six synthesized compounds were screened for enzyme inhibition against MbtA, the 
molecular target for 17 in M. tuberculosis. 7KH UHVXOWV VKRZHG D ELDV IRU WKH &¶-endo for 
DFWLYLW\&¶IOXRURP0&¶IOXRURPM against M. tuberculosis H37Rv ). It was also 
found WKDW&¶-endo fluorination improved pharmacokinetic (PK) parameters in i.v. and p.o. 
measurements ZKHQFRPSDUHGWRWKH&¶IOXRURDQDORJ. 
Aldrich further probed structure-activity relationship of SAL-AMS analogs 19, with ten 
compounds encompassing a variety of structural modifications (Figure 7),[40] again 
FRQFOXGLQJ&¶IOXRULQDWLRQ54) being the most successful modification, maintaining activity 
against MbtA whilst improving PK properties. Other modifications, enhancement of 
OLSRSKLOLFLW\DQGSURGUXJDSSURDFKHVHJHVWHUSURGUXJVRI&¶-fluorosulfamide isostere 21 
vs. parent compound 20 led to inferior PK data (plasma stability at t1/2  typically lower than 
20).[41] An inherent limitation of SAL-AMS 17 is degradation via cyclonucleoside 
formation.[42] Although this does not occur in 8-aza-3-deaza adenines (e.g. 22) as they lack the 
correctly positioned N required for intramolecular cyclisation, bioactivity against whole-cell 
M. tuberculosis H37Rv was limited and only revealed under iron deficient conditions for all 
synthesized analogs (e.g. R1 = Ph MIC 25 PM).[43] In contrast to adenosine derivatives, 
inhibition of the transition state of MbtI-catalyzed reaction of 13 to isochorismate 14 by 
compounds such as 23 was found to be less promising (<10% inhibition of MbtI at 100 
PM).[44]  
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Figure 7. Additional SAL-AMS analogs synthesized to improve PK properties. 
3.3. Regulation of Siderophore Biosynthesis via Quorum Sensing Systems 
Bacteria are able to adapt the expression of genes in response to cell density via 
intercellular FRPPXQLFDWLRQ 7KH ³ODQJXDJH´ RI WKLV FRPPXQLFDWLRQ DUH VPDOO VLJQDOOLQJ
molecules (autoinducers), which are secreted into the surrounding medium.[45] The 
phenomenon of quorum sensing (QS) uses the principle that at low cell densities the 
concentrations of these autoinducers are too low to bind to their receptors. Only when the 
concentration of the signal has reached a critical threshold the autoinducers bind to specific 
cognate receptor proteins, which then start to regulate transcription by activating (or 
repressing) the expression of genes under QS control (Figure 8).[46] 
 
Figure 8. Principle of quorum sensing. N-acyl homoserine lactones (AHL) are the best known bacterial auto-
inducers; R is the autoinducer receptor protein, usually coupled to a transcriptional regulator (redrawn from Ref. 
[47]). 
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A large variety of physiological processes, among which are biofilm formation and the 
expression of key virulence factors such as proteases and siderophores, are regulated by QS. 
 
Figure 9. QS signalling molecules. 
Mediators of QS signalling can be broadly divided into four major classes:[4b,48] i) N-acyl 
homoserine lactones (AHLs) 24, produced by many Gram-negative bacteria; ii) oligopeptides 
(e.g. autoinducing peptides (AIPs) 25), made of 5±20 residues, generally produced by Gram-
positive bacteria; iii) autoinducer-2 (AI-2) 26, a group of furanones derived from 4,5-
dihydroxy-2,3-pentanedione (DPD) 27, produced by both Gram-negative and Gram-positive 
bacteria; iv) 2-alkyl-4-quinolones 28 including 2-heptyl-4(1H)-quinolone 28a (HHQ) and the 
pseudomonas quinolone signal (PQS) 2-heptyl-3-hydroxy-4(1H)-quinolone 28b (Figure 
9).[49,50] 
QS based systems may play different roles in controlling siderophore production. The AHL-
mediated quorum sensing-disrupter 29 (Figure 10) from the marine red alga Delisea pulchra 
was found to inhibit the formation of the siderophore produced by P. putida F1 in a 
concentration-dependent manner (the addition of 29 decreased siderophore concentration by 
1.7 fold at 20 Pg mL±1 and 40 Pg mL±1 and 2.3 fold at 100Pg mL±1). On the contrary, 
siderophore synthesis in P. aeruginosa PAO1 was stimulated (it induced siderophore 
production  by 3.5-fold at 100 Pg mL±1).[51] 
 
Figure 10. Selected compounds interfering with QS systems based on 24. 
10.1002/anie.201701586Angewandte Chemie International Edition
This article is protected by copyright. All rights reserved.
15 
 
Scoffone aimed at specifically inhibiting the Burkholderia cenocepacia QS-system, which 
comprises the receptor CepR and the synthase CepI catalysing synthesis of N-octanoyl-L-
homoserine lactone.[52] Out of ten different compounds assayed against recombinant CepI, 
four were effective inhibitors, with IC50 values in the micromolar range (e.g. 30, IC50 = 5 µM 
and 31, IC50 = 30 µM, Figure 10). The best compounds interfered with protease and 
siderophore production and with biofilm formation, and showed good in vivo activity in a 
Caenorhabditis elegans infection model. These compounds, when tested on human cells, 
showed very low toxicity (significant effects on HeLa cell growth were observed only after 
48h treatment at a concentration of 100 PM). 
P. aeruginosa possess a complex QS network, which comprises representatives of the 
compound classes 24 and 28 and which is involved in the regulation of a number of virulence 
phenotypes. In particular the compound 28b plays multifunctional roles in iron entrapment.[53] 
28b not only is involved in the regulation of the biosynthesis of the siderophores pyoverdin 
and pyochelin 2 but it also forms iron complexes, which are not siderophores but instead 
appear to trap iron at the cell surface and facilitate siderophore-mediated iron uptake. 
Moreover, they control the expression of iron-regulated and iron-independent genes.[53] Thus, 
inhibition of the 28b signalling cascades leads to inhibited production of QS-controlled 
virulence factors and of the multi-level iron acquisition systems of P. aeruginosa. In the 
following some examples are mentioned. 
Several studies have focused on the discovery of inhibitors of the receptor of 28, PqsR. The 
synthesis of various PqsR-antagonists was described, which had high affinity for the PqsR 
ligand-binding domain and strongly inhibited PqsR activity in a heterologous E. coli-based or 
P. aeruginosa reporter system.[54±56] Examples are 28a analogs (compound 32; IC50 = 51 
nM),[54] the hydroxamic acid 33 (IC50 = 12.5 PM)[55] and 2-aminooxadiazole 34 (EC50 = 7.5 
PM) (Figure 11).[56] In P. aeruginosa reduced production of the redox-active phenazine 
antibiotic and of the virulence factor pyocyanin 35 was observed. 35 reduces Fe3+ to 
bioavailable Fe2+, leads to damage of host cells, alters immune responses and contributes to 
the persistence of P. aeruginosa in the lung of cystic fibrosis patients.[57] 
 
Figure 11. Selected compounds interfering with the QS system based on 28b and structure of pyocyanin 35. 
Recently, the structure of the PqsR co-inducer binding domain has been solved.[58] This 
structural information was used to guide the synthesis of a series of quinazolinone analogs as 
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possible PqsR antagonists. Compound 36 was identified as a potent inhibitor of the 28b-
dependent QS system (IC50 = 5 PM), strongly reducing pyocyanin production, lectin 
expression, and biofilm development. Notably, also the crystal structure of PqsR bound to 36 
was determined, providing valuable data for further development. Benzimidazole 37 was 
among the first compounds to reduce formation of antibiotic-tolerant persister cells.[59] 
Elucidations of the 28 biosynthesis mechanisms[60±62] have allowed a rational design of QS 
biosynthesis inhibitors, such as the 2-benzamidobenzoic acid derivatives 38 (IC50 PqsD = 1.2 
PM),[63] 5-aryl-ureidothiophene-2-carboxylic acids 39 (IC50 PqsD = 6 PM)[64] and indoles 40±
42. These latter have been shown to inhibit 28b, pyocyanin 35, pyoverdine, and rhamnolipid 
production in P. aeruginosa.[65,66]  
Thus, though these compounds do not directly target siderophore biosynthesis, they indirectly 
inhibit iron acquisition systems, as they interfere with the regulation of their expression.  
When QS regulation, and thus the signaling molecules 24, are no longer needed, they are 
converted to the corresponding 3-acyltetramic acids (3ATA), for example the autoinducer N-
dodecanoyl-L-homoserine lactone of P. aeruginosa is converted to 3-decanoyl-5-(E-
hydroxyethyl)pyrrolidine-2,4-dione 43a through an irreversible, nonenzymatic Dieckmann 
reaction (Figure 12).[67,68]  
 
Figure 12. Conversion of an autoinducer 24a to an antibacterial 3ATA. 
This conversion may even be induced by metal chelation. The 5-(E-hydroxyethyl) substituted 
3ATA are potent antibacterial agents acting by dissipating both the membrane potential and 
the pH gradient of Gram-positive bacteria.[69] They also elicit a negative feedback to biofilm 
formation by withdrawing the necessary iron. 
Williams proved that synthetic 5-(E-hydroxyethyl) substituted 3ATA may also inhibit QS in 
S. aureus by acting as negative allosteric modulators of the autoinducer receptor resulting in 
vastly reduced bacterial virulence. The concentration window between the desirable reduction 
of the virulence and the undesirable inhibition of the growth of bacteria can be enlarged by 
adjusting the length of the 3-acyl side-chain.[70] 
3.4. Competition for Iron 
3.4.1. Siderophore Cheating 
The concept of cheating is common in bacterial iron acquisition,[71] where cheating cells 
unable to produce siderophores rely on neighboring organisms for production. In recent 
experiments examining co-cultivated assemblages of environmental bacteria, certain isolates 
were found to be completely dependent on neighboring bacteria for growth.[72,73] Chemical 
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dissection of this dependency confirmed siderophores have a critical role, supporting the idea 
that siderophore piracy is a potentially common and essential survival strategy for some 
bacteria. Certain pathogenic bacteria appear to engage in siderophore piracy, even among 
nearly clonal strains. P. aeruginosa populations accumulate siderophore (pyoverdine)-
negative mutations during host infections, and the surviving mutants presumably acquire iron 
by scavenging iron-pyroverdine complexes produced by neighboring cells.[74] Growing 
evidence suggests that a number of bacterial pathogens cheat not only by intercepting intact 
siderophores, but also by utilizing siderophore degradation products. Structural and 
biophysical studies on Campylobacter jejuni, an organism not known to produce their own 
siderophores revealed how CeuE, a periplasmic siderophore binding protein can scavenge 
µVHFRQG-KDQG¶HQWHUREDFWLQK\GURO\VLV IUDJPHQWVZLWKKLJKDIILQLW\.[75] This ability contrasts 
starkly with more typical Fe3+ uptake involving intact hexadentate siderophores. 
Iron piracy is also documented in organisms that can produce their own siderophores. 
Siderophore piracy is genomically evident in Rhodopseudomonas palustris, where 
siderophore receptors far outnumber siderophore biosynthetic loci.[76] In the clinic, a number 
of pathogenic Staphylococci are documented to utilize hydroxamate and catecholate 
siderophores, molecules they lack biosynthetic genes for.[33] Complex siderophore piracy 
phenotypes have emerged during studies on differentiation and stress response in 
actinomycete bacteria. Actinobacterial competition screens, historically detecting 
siderophores[77] and ionophores,[78] recently led to the discovery of the potent mixed-ligand 
siderophore amychelin. Further characterization revealed Amycolatopsis sp AA4-produced 
amychelin controls co-cultivated Streptomyces coelicolor bacterial development in part by 
direct siderophore-mediated iron competition.[79] But Amycolatopsis also affects S. coelicolor 
by scavenging S. coelicolor¶V ferrioxamine siderophores, further depriving the co-cultivated 
strain of iron. 
In studies on food-safe bacteria having antibacterial properties, a series of human gut 
associated Bifidobacterium strains were discovered that strongly inhibits the growth of Gram-
negative and Gram-positive bacteria in an iron dependent manner suggestive of siderophore 
competition.[80] Of note, Bifidobacterium RecB1 inhibited the common lab bacteria 
Escherichia coli K-12 and Micrococcus luteus in addition to the serious gut pathogens 
Clostridum perfringens and Clostridum difficile. Although incomplete siderophore-linked 
bacterial growth inhibition was noted above, the clear broad spectrum-antibiosis demonstrated 
by these Bifidobacteria is striking. Unfortunately the siderophores responsible remain 
uncharacterized. 
3.4.2. Synthetic Iron Chelators 
Synthetic high-affinity iron chelators can have a biostatic effect on pathogens when they 
decrease the amount of Fe3+ that can be utilised by a pathogen. This biostatic effect relies on 
the competition, both thermodynamically and kinetically, between natural microbial 
siderophores and the added synthetic iron chelator. In the design of synthetic iron chelators it 
is essential to ensure that the iron complexes formed cannot be taken up and utilised by a 
pathogen, as this could lead to growth promotion rather than growth inhibition. Since 
coordinating groups that are commonly found in natural siderophores are likely to be 
recognised by microbial transporters, these groups should be avoided in the design of 
10.1002/anie.201701586Angewandte Chemie International Edition
This article is protected by copyright. All rights reserved.
18 
 
synthetic antimicrobial iron chelators. Synthetic chelate ligands, such as 
polyaminocarboxylates, organophosphonates, 8-hydroxyquinolines and related compounds 
have long been known to possess bacteriostatic properties.[81,82] Also hydroxypyridinones 
(HOPOs) 44±46 fulfil this requirement and hence have attracted interest as alternative iron-
binding units (Figure 13).[81,83±88]  
 
Figure 13. Structures, pKa and pFe values of selected hydroxypyridinones (pFe3+ = ±log[Fe3+] when  
[Fe3+]total = 10±6 M and [ligand]total = 10±4 M at pH 7.4).[83] 
In their deprotonated form, these ligands provide adjacent oxygen-donors that can form 5-
membered chelate rings and are able to compete thermodynamically with the chelating units 
commonly found in natural siderophores, such as catecholates, hydroxamates and 
hydroxycarboxylates. Since HOPO groups are rarely found in siderophores, their iron 
complexes were expected not to be taken up by receptor-mediated bacterial transport. Of the 
three types of metal-chelating HOPOs (Figure 13), the 3,4-HOPOs have the highest affinity 
for Fe3+, as reflected by their high pFe3+ values, a property that led to their application in 
chelation therapy. Whilst bidentate ligands, such as deferiprone, are now established drugs in 
the treatment of iron overload, the development of antimicrobial iron chelators has moved on 
from bidentate to hexadentate ligands.[83,84] Since size restrictions do not apply to 
extracellularly-acting antimicrobial metal chelators, the higher thermodynamic and kinetic 
stability of the Fe3+ complexes of hexadentate ligands is of advantage in the competition with 
natural siderophores, especially at low concentrations. 
Hexadentate ligands of type 47 (Figure 14) for example, have a higher affinity for Fe3+ and 
higher antimicrobial activity than diethylenetriaminepentaacetic acid (DTPA 51)[84,85] (Figure 
15) and their Fe3+ complexes are not taken up by E. coli or S. aureus.[83] Hexadentate 3,4-
HOPOs 48 have pFe3+ values of over 30 and were found to inhibit the growth of both Gram-
positive and Gram-negative bacteria, including methicillin-resistant S. aureus and clinical 
isolates of P. aeruginosa.[86,87] 
Even though 1,2-HOPOs contain weaker Fe3+-coordinating groups, a number of 1,2-HOPOs 
was recently shown to act as antimicrobial agents.[88] Their lower pKa values, typically 
around 6 (Figure 13), ensure deprotonation at physiological pH and the resulting negatively 
charged ligands are less likely to penetrate host cells. Of the series of 1,2-HOPOs tested,[88] 
the hexadentate ligand 49[89] showed the most promising biostatic effect against a range of 
pathogenic bacteria, whilst HOPO ligand 50 was somewhat less effective. These observations 
confirm that the amide linkers and/or flexibility of the backbone are important design criteria 
to be considered in future studies. 
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Figure 14. Structures of selected hexadentate siderophore mimics. 
The antimicrobial effect of ethylenediaminetetraacetic acid (EDTA) was documented as early 
as 1954.[90] Today the hexadentate ligand is used in many domestic, industrial and medicinal 
applications, in particular disinfection and surface cleaning. The bacteriostatic properties of 
aminocarboxylate ligands, such as EDTA and DTPA 51, are associated with their ability to 
strongly chelate Fe3+, however, these ligands also bind a range of other metal ions. The 
chelation of Ca2+ and Mg2+, for example, disrupts and permeabilizes the outer membrane of 
Gram-negative bacteria, thereby enhancing the susceptibility of the cells to antibiotics. 
Further advantages of EDTA are its low toxicity. 
 
Figure 15. Examples of aminocarboxylate-based metal chelators. 
The widespread use of EDTA and DTPA 51 combined with their low biodegradability has led 
to their accumulation in wastewater and may cause long-term changes in environmental metal 
speciation.[82] The urgent need for biodegradable alternatives has led to the development of 
substitutes, such as 52±54. The antimicrobial activity of 53 is slightly higher than that of 
EDTA. In addition, 53 is also more potent than EDTA in enhancing the effectiveness of 
antibacterial agents by increasing the permeability of the bacterial membrane.[91] 
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Another group of metal chelators is based on 3-acyltetramic acids (3ATA) 43. They 
occur in nature as metabolites of bacteria, cyanobacteria, molds, fungi, and sponges.[92] They 
are comprised at the minimum of polyketides and D-amino acids and normally exist as 
mixtures of interconverting rotamers and tautomers. 3ATA frequently show antibacterial, 
antiprotozoal, antifungal, herbicidal, or antitumoral activity. These biological effects are 
thought to originate from the accuracy of fit of their polar tris-ß-keto unit into the active sites 
of kinases and phosphatases, from their amphiphilic detergent-like nature which allows them 
to interfere with plasma membranes and to act as ionophores, and from their high metal 
affinity leading to an accumulation or sequestration of biologically relevant metals. 
3ATA form chelate complexes with a range of metal ions. The two possible complex isomers 
E-55 and Z-55 are far less polar than the free ligands, they do not normally interconvert under 
biological conditions, they are both synthetically accessible and readily distinguishable via IR 
spectroscopy,[93,94] and they may have different biological properties (Figure 16). 
 
Figure 16. Tautomers and metal chelate complexes of 3ATA. M = metal ion; Ln = number of auxiliary ligands.  
Metal chelation seems to be crucial for the transport of certain natural tetramic acids and most 
of them were actually isolated as metal chelate complexes.[92e,95] Tenuazonic acid (43b: R1 = 
H, R2 = Me, R3 = CHMeEt), a toxic L-isoleucin-derived metabolite of Alternaria tenuis, was 
isolated as a 10.5 : 2 : 1.5 mixture of its chelates with Mg2+, Ca2+, and Na+, aside of trace 
amounts of Zn2+ and K+ chelate complexes, which reflects the affinity of tenuazonic acid for 
these metals.[96] However, synthetic 3ATA chelates of other transition metal ions were also 
reported, e.g. of Cu2+,[97] Ni2+,[93a] and Mn2+.[98] Such chelate complexes often show biological 
effects different from those of the parent 3ATA. The tendency of 3ATA to form defined metal 
chelate complexes with a conformationally rigidified planar geometry was even utilized for 
their synthesis (Figure 17).[99,100] 
The overall formation constants for the complexation of Fe3+ by 3ATA are similar to those of 
typical siderophores such as pyoverdin.[67] However, unless applied in high concentrations, 
3ATA are inferior to the latter in terms of iron chelation at physiological pH values due to 
their statistic disadvantage as merely bisdentate ligands and because of their relatively high 
acidity which favours stable complexes only at relatively low pH. As a consequence 
Fe3+(3ATA±H)3 complexes have pM values distinctly lower than those of ferrisiderophores. It 
is worth noting that the capacity of 3ATA to form iron complexes and so sequester iron in 
bacteria is not necessarily causative for their growth inhibition or cytotoxic effect. This was 
shown by Lebrun by treating bacteria with tenuazonic acid and its octahedral (3:1) Fe3+ 
complex only to find them equally cytotoxic.[88] 
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Figure 17. Metal chelate assisted syntheses of methiosetin 58 and macrocidin A 61. TIPS = tris(isopropyl)silyl; 
OTf = CF3SO3; TBAI = tetrabutylammonium iodide; M = Al or La; Ln = number of auxiliary ligands. 
Quite a few other 3ATA with proven affinity for iron have not even been tested for 
antibacterial activity, e.g. macrocidin A 61 which was lately shown to interfere with vital 
enzymes of the photosystem II and of the chlorophyll and carotinoid biosynthesis by 
sequestering iron and magnesium.[101,102] 
 
Figure 18. Antibacterial activity of stereoisomers of torrubiellone D 62 against E. coli strains. E. coli K12: 
wildtype; E. coli ǻTolC: mutant lacking the ArcABíTolC efflux system; E. coli D21f2: supersusceptible mutant 
with truncated lipopolysaccharide core.  
It was also shown that synthetic analogs and precursors of the macrocyclic 3ATA 
aburatubolactam and macrocidin A 61 can have antibacterial activities.[103,104] An antibacterial 
screening of the fungus metabolite torrubiellone D 62 revealed distinctly different activities of 
its four stereoisomers against drug-susceptible E. coli strains (Figure 18).[105] The influence of 
metal ion concentrations, in particular of Fe3+, was not yet studied. 
Growth inhibiting effects of the removal of metal ions were also observed when Zn2+-specific 
chelators are present. For example, the endogenous protection of the human skin from 
Escherichia coli infection was attributed to the Zn2+-chelating activity of the protein psoriasin, 
which is secreted by keratinocytes, i.e. the cells of the upper skin layers.[106] Also synthetic 
Zn2+-chelators, such as N,N,N´,N´-Tetrakis(2-pyridylmethyl)ethylene diamine (63, TPEN) and 
dithiolopyrrolones, such as reduced holomycin 64 (Figure 19), are reported to inhibit growth 
rates of Gram-positive bacteria, such as Streptococcus pyogenes,[107] and Gram-negative 
bacteria, e.g. Escherichia coli.[108] The reduced holomycin particularly inhibited the activity of 
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zinc-dependent metalloenzymes, such as class II fructose bisphosphate aldolase (85±90% 
inhibition at 25 µM), an essential enzyme for E. coli growth, and NDM-1 (IC50 = 0.15 µM), 
the New Delhi metallo-ß-lactamase, which is responsible for resistance to all types of ß-
lactam antibiotics. As both 63 and 64 are membrane-permeable it was speculated that their 
activity is mainly due to competition with intracellular proteins for Zn2+. 
 
Figure 19. Synthetic Zn2+-chelators. 
The application of metal ion chelators enhances nutrient stress for the pathogen, so that 
affected microorganisms have to compete with the added synthetic chelator. In the case of 
iron starvation this leads to increased production of high-affinity siderophores and this has a 
metabolic cost associated with it. It is not yet proven, whether a similar metallophore 
production is also observed in response to limitations of other metal ions. In addition, 
synthetic ion chelators can work synergistically with existing antibiotics. It is likely that the 
antimicrobial effect of metal ion chelators will vary with the type of pathogen to be targeted, 
depending for example on the set of siderophores it relies on. However, synthetic iron 
chelators are already used in topical applications, for example in surface cleaning, wound 
healing and in the treatment of nail and eye infections. The development of antimicrobial 
metal ion chelators for systemic use, however, is facing additional challenges. In particular, 
interferences with WKHKRVW¶VPHWDOORHQ]\mes and immunodefence system have to be avoided. 
3.5. 7KH³7URMDQ+RUVH´Strategy: Utilization of the Siderophore Transport Machinery 
3.5.1. Trojan Horses from Nature 
Hybrid compounds comprised of a siderophore fused to an antibacterial component, so 
FDOOHG³Trojan KRUVHV´ have long been known to the literature, in fact predating the discovery 
of siderophores themselves.[109,110] They depend on recipient cell siderophore transporters for 
active transport into the cytosol, where subsequent cleavage releases the free antibiotic to kill 
susceptible cells. 
Two major classes of siderophore-linked antibiotics are documented in the literature, 
categorized by producing bacteria and siderophore moiety (Recently reviewed by Johnstone 
and Nolan[111]). The sideromycins (including salmycins, albomycins and ferrimycins) are 
produced by Gram-positive soil actinomycetes. Typical examples are shown in Figure 20. 
These Trojan horses are characterized by a ferrioxamine class siderophore linked to an 
antibiotic.[112] The antibiotic moiety found in each varies by sideromycin: whereas salmycin 
65 carries an aminoglycoside as warhead, the warhead of albomycin į2 66 is the seryl 
adenylate 67 analog and inhibitorof seryl-tRNA synthetase SB-217452 68.[113] 
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Figure 20. Sideromycins, salmycin A 65 and albomycin į2 66. The latter contains 68, a seryl adenylate analog as 
warhead. Structurally diverse ferrioximine siderophore substructures are highlighted in red.  
In contrast to the sideromycins, microcin-class siderophore conjugates 69, e.g. MccE492 69a, 
MccM 69c, and MccH47 69d are sourced from Gram-negative enterobacteria.[114] These 
highly similar compounds share a salmochelin-type siderophore,[115] and the bioactive 
warhead conjugates are short antimicrobial peptides (Figure 21).  
 
Figure 21. The invariant siderophore moiety of microcin siderophores 69 is linked to various antimicrobial 
peptides with little overall identity, excepting a semi-conserved poly-serine enriched motif and strictly conserved 
carboxy terminal serine where the peptides are linked to the siderophore glycosyl moiety by MceIJ[114,118,119] 
(grey box). 
The bioactivity of microcin siderophores is limited to certain Gram-negative enterobateria, 
but their incorporation of salmochelin makes them active against bacteria FepA, Cir and Fiu 
catecholate siderophore transporters.[116,117] 
Bacterial resistance to the sideromycins has been documented, often arising from mutations in 
siderophore transporters.[109] These mutants seem to be less viable than their wildtype 
counterparts,[109] perhaps because iron acquisition is perturbed during the selection of resistant 
mutants. This phenomenon, where a measurable fitness cost is revealed in resistant mutants, 
may indicate hidden value for drug development in sideromycin-type antibiotic leads. One 
clinically utilized antibiotic with similar resistance attributes is fosfomycin (trade name 
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Monurol), used to treat non-complicated urinary tract E. coli infections. Clinical resistance is 
scarce, but commonly encountered under laboratory conditions.[120] Fosfomycin resistance 
maps to a number of genes encoding transporters required for drug uptake. Mutants in these 
genes appear to suffer in growth rate, imposing a fitness cost on surviving bacteria and 
mutants are more easily cleared in a bladder infection model. Thus molecules having novel 
mechanisms of action, but suffering from rapid resistance development could still have 
clinical value if mutants are reduced in virulence or other fitness parameters critical in vivo.  
3.5.2. Genome Mining for new Siderophore Antibiotics 
A vast literature exists supporting the genomics-guided discovery of biosynthetically 
common and long studied families of molecules such as non-ribosomal peptides and 
polyketides. Far fewer studies have addressed the gene clusters of siderophore-microcins and 
sideromycins biosynthesis, and likewise, few genome mining efforts for siderophore 
antibiotics have been undertaken. This is changing, and the siderophore-microcins MccM 69c 
and MccH47 69d were recently discovered after comparing the genomes of an array of 
microcin producing Klebsiella and Escherichia strains.[121] A bioassay testing MccE492 69a, 
MccM 69c and MccH47 69d against a panel of gram negative pathogens including E. coli, K. 
pneumonia, Enterobacter cloacae, and Salmonella enterica serovars Typhimurium and 
Enteritidis revealed E492 is generally more active than M or H47. Despite these newer 
microcins having less desirable activity profiles than E492, genomic data indicate additional 
microcin siderophores await discovery, including MccI47 69e and MccG492 69b. 
Spectrometric data consistent with MccI47 69e detection have been obtained, but low-level 
production has impeded further characterization and MccG492 69b remains chemically 
undiscovered. Engineering work is likely required to increase MccI47 69e and MccG492 69b 
production for activity testing. 
Genome mining for new microcin siderophore conjugates is fairly straightforward and 
will likely lead to new bioactive members in the future. Biosynthetic loci encoding these 
conjugates are easily recognized in genomes by the presence of genes similar to mceIJ. 
Enzymes encoded by these genes link the C-terminal serine of peptide E492 to its cognate 
siderophore glycosyl moiety.[119] As expected, orthologs of these enzymes are encoded in the 
MccE492 69a, MccM 69c and MccH47 69d biosynthetic loci, consequently making mceIJ 
genes useful bioinformatic hallmarks for siderophore-microcin locus identification. Further, 
the discovery of MccM 69c, MccH47 69d, MccI47 69e and the prediction of MccG492 69b 
are the products of a single work.[121] Drastically increasing the number of class IIb microcins 
available for study, these results illustrate the discovery potential inherent to genomics-guided 
natural products discovery.  
In contrast to the emerging body of biochemical and genetic data used to support genome 
mining for microcin-siderophores, biosynthetic data for actinobacterial sideromycin 
production is nearly non-existent. A single study revealing the albomycin į2 biosynthetic 
locus[122] is the only such inquiry thus far. This is surprising considering the growing 
availability of sequenced actinomycete genomes and the long recognized drug interest in the 
sideromycins. To discover the albomycin biosynthetic locus in Streptomyces sp ATCC700974 
in the absence of albomycin-specific genes to guide genomic searches, Zeng searched for 
ornithine N-hydroxylase homologs commonly associated with actinomycete 
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ferrioxamine/ferrichrome siderophore loci. Siderophores of this type are substructures of the 
sideromycins. Once the albomycin warhead genes were identified, homology searches in 
other bacteria led to the identification of a potentially novel, yet chemically undiscovered 
sideromycin encoded in the genome of Streptomyces sp. C.[122] Aside from this single 
predicted molecule, a genomics guided path to discover additional sideromycins remains 
unclear. In contrast to the microcin siderophores, where specialized locus-specific enzymes 
(mceIJ) can help guide genomic discovery, the sideromycins have structurally dissimilar 
warhead moieties, and share sparingly few substructural elements from their incorporation of 
variant ferrioxamine or ferrichrome type siderophores.[111] While a large scale Orn N-
hydroxylase-based search for new sideromycins in other actinomycete genomes could be 
attempted, such a strategy is unfavorable. This is because N5-OH-Orn is a common 
intermediate in many actinomycete siderophore and other secondary metabolite pathways.[123] 
Searches using Orn N-hydroxylase to survey genomes would identify far more non-
sideromycin loci compared to desirable sideromycin hits. Considering this, our ability to 
genomically recognize new sideromycin loci is significantly hampered. Should additional 
sideromycin-producing organisms be sequenced in the future, new data enabling more 
efficient genomic discovery may emerge. 
3.5.3. Synthetic Trojan Horses 
Inspired by the sideromycins a range of synthetic Trojan horse conjugates were 
developed over the past 50 years, with the aim of exploiting active bacterial nutrient uptake, 
thereby evading resistance associated with a reduction of membrane permeability or an 
increase in efflux (for recent reviews see ref.[124±127]). 
Uptake studies with various synthetic tris-bidentate chelators with different combinations 
of catechol, hydroxamate, and (o-hydroxy)phenacyl ligands and receptor-defective E. coli 
mutants showed that their corresponding Fe3+ complexes were actively internalized only via 
catecholate rather than via hydroxamate receptors. This holds also true for their conjugates 
with E-lactam antibiotics, e.g. conjugates 70 (Figure 22).[128] It was also shown that simplified 
mimics of the natural siderophores parabactin and agrobactin, carrying an o-
hydroxybenzamide instead of the 2-(o-hydroxyphenyl)oxazoline ligand, unlike the originals, 
were fully functional siderophores in E. coli.[129] 
Of the many siderophore-ȕ-lactam conjugates reported to date, at least three have undergone 
further development by the pharmaceutical industry (Figure 22):[130] MC-1 72,[131] BAL30072 
71[132] and S-649266 (Cefiderocol) 73.[133] The latter is currently in phase 2/3 clinical trials. 
Interestingly, all three conjugates rely on bidentate iron-chelating units that resemble the 
unusual 3,4-dihydroxybenzoyl unit found in petrobactin, a stealth siderophore that evades 
capture by the human immune system protein siderocalin.[134] 
In addition, glycosylated enterobactin derivatives that were inspired by stealth siderophores of 
WKHVDOPRFKHOLQW\SHZHUHOLQNHGWRȕ-lactams and shown to evade siderocalin binding.[135] 
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Figure 22. Siderophore-E-lactam-conjugates as Trojan horses for antibiotics. 
 
Figure 23. Examples of fluoroquinolone conjugates. 
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The inhibition of cytoplasmic drug targets has also been attempted. Studies with 
fluoroquinolone antimicrobials investigated a variety of derivatised siderophore components 
(Figure 23), including pyoverdin (74),[136] pyochelin derivative 75,[137] citric acid derivative 
76,[138] staphyloferrin (77)[139] and enterobactin derivative 78,[140] and highlighted the 
necessity of biolabile linkers that allow the release of the antimicrobial inside the bacterial 
cell. Very recently, Miller has patented a conjugate of an Acinetobacter baumannii specific 
siderophore with daptomycine, which expanded the scope from strictly Gram-positive to 
Gram-negative bacteria.[141] 
Finally, also conjugates with membrane-targeting compounds, such as ionophors and 
lantibiotics, were synthesized. Ionophors recognize specific ions even in complex mixtures 
and facilitate transmembrane transport.[142] Typical examples are synthetic crown ethers, 
azacrowns and the like as well as natural polyether antibiotics, e.g. lasalocid A 79.[143] It is 
well known that crown ethers and related macrocycles display pronounced antimicrobial 
properties, which is due to the formation of cation-transporting pores in bacterial cell 
membranes thereby irreversibly disturbing the ion gradient.[144,145] In addition, crown ether 
derivatives may also function as siderophore mimics thus competing with the bacterial iron 
scavenging system.[146] Ramazanov reported that azamacrocycle 80 inhibited the growth of 
Staphylococcus aureus (MIC 1 Pg mL±1) (Figure 24), but did not affect Escherichia coli and 
Klebsiella sp..[146] However, when magnetite nanoparticles were functionalized with azacrown 
81 via non-covalent interactions, the resulting hybrid material inhibited both E. coli 
(MIC 0.5 Pg mL±1) and Klebsiella sp. (MIC 0.5 Pg mL±1). The complementary acitivity 
profile was rationalized by the formation of a Fe3+ complex, which is shuttled inside the 
bacterial cell through the siderophore uptake system in a Trojan horse manner. Recent work 
by Gokel revealed that shuttling by lariat ethers 81 enhanced the potency of antibiotics 
rifampicine and tetracycline against E. coli 20fold upon co-administration with 81 in a 
synergistic fashion.[147,148] 
The combination of pore-forming crown ethers with siderophores provides an additional 
strategy to increase the transport of Fe3+ through the bacterial cell membrane and thus 
interfere with bacterial iron homeostasis. Following this approach Crumbliss studied 
extensively the supramolecular interaction of lariat ether carboxylic acids, i.e. crown ethers 
carrying a peripheral alkyl carboxylate arm (as hosts) with the natural siderophore 
desferrioxamine B (DFB) (as guest).[149] The corresponding Fe3+ complex ferrioxamine B 
FeHDFB+ forms a ternary second sphere complex 82 with the lariat ether via the terminal 
ammonium unit, while the carboxylate arm further contributes to the complex stability via 
electrostatic interactions (Figure 24). Complex 82 was compared with the corresponding host-
guest assemblies derived from lasalocid A 79 and ferrioxamine B[150,151] and carrier-facilitated 
bulk liquid membrane transport of the Fe3+ siderophore was achieved.[152,153] Based on this 
precedent Orcutt developed liposomes containing 80 in the bilayer membrane, which 
selectively recognized and extracted FeHDFB+ preferably with respect to Ca2+, Na+  and K+ 
from the surrounding aqueous phase.[153] Although initially intended as chemical sensor for 
monitoring of Fe3+ availability in seawater, this liposome-based nanodevice for sequestering 
siderophore-bound Fe3+ might be useful to study host-pathogen interactions. 
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Figure 24. Ionophors and conjugates to siderophores. 
Lantibiotics also lead to the formation of pore complexes, which severely disturb the 
intra- and extracellular ion concentrations leading to bacterial cell death. An attractive feature 
of lantibiotics is their low tendency to develop resistance.[154,155] They are small polycyclic 
peptides (< 10 kDa) produced by prokaryotes, which belong to the class of endogeneous host 
defensive peptides. They are an important part of the innate bacterial immune system to fight 
other pathogenic bacteria.[156,157] A prominent member of this family is nisin (Figure 25) 
produced by Lactococcus lactis. Nisin contains several structural features unique for this type 
of peptides, namely the amino acids lanthionine (Lan), 3-methyllanthionine (MeLan), (Z)-
dehydrobutyrine (Dhb) and dehydroalanine (Dha) as well as thioether bridges.[158,159] 
 
Figure 25. Schematic representation of the structure of nisin (redrawn from ref. [160]). 
Recent work by Rijkers showed that modification of nisin did neither compromise 
antibacterial activity against Bacillus subtilis and Staphylococcus aureus nor the membrane 
permeabilization.[160] To enhance the transport through the outer membranes of Gram-
negative bacteria Vederas synthesized conjugates 83±85 of the lantibiotic gallidermin with the 
three different siderophores pyochelin 2, agrobactin and desferrioxamin B, respectively, 
employing squaric acid methylester as a bifunctional linker (Figure 26).[161] 
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Figure 26. Siderophore-monomethylsquarate esters 83±85.[161] 
While the conjugates retained at least some antibacterial activity of gallidermin against the 
indicator organism Lactococcus lactis subsp. cremoris HP, an unexpected growth promotion 
rather than antibacterial activity was observed against Pseudomonas aeruginosa suggesting 
that the conjugates kept their siderophore activity but failed to permeabilize the inner 
membrane. 
These results indicate that the synthesis of Trojan horses requires careful choice of the 
siderophore moiety, the linker and the antibiotic. 
3.5.4 Siderophore quenching 
Siderophores are chelators showing specificity for Fe3+, but are able to also complex other 
metal ions though with different affinities.[162] Ga3+ is structurally rather similar to Fe3+ so that 
in almost all complexes Fe3+ can be replaced by Ga3+. Thus, bacterial siderophores can be pre-
loaded with Ga3+ and transport Ga3+ into the cells, where it replaces Fe3+ also in proteins 
without having the redox properties of Fe3+. Resulting antibacterial effects are based on the 
combination of the utilization of the siderophore transport machinery via competitive binding 
of Ga3+ to siderophores with Fe3+ depletion. The area has recently been reviewed.[163] Gallium 
citrate, for example, shows activity against a range of Gram-negative bacteria, with MICs 
ranging from ~1 to 5 µg/ml. Importantly, in comparison with conventional antibiotics, 
resistance to the toxic effects of Ga3+ is slower to develop and Ga3+-containing compounds 
remain active even against bacteria that grow in biofilms.[164] Phase 1 clinical trials with an 
intravenous gallium nitrate-citrate formulation have shown promising results in cystic 
fibrosis-associated lung infections and in January 2017 Aridis Pharmaceuticals announced 
plans for a phase 2a clinical trial with gallium citrate (PanaecinTM), supported by an award 
from the Cystic Fibrosis Foundation. [http://www.aridispharma.com/panaecin.html] 
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3.6. Siderophore Transport into the Cell 
Fe3+-loaded siderophores are recognized by receptors in the outer membrane of Gram-
negative bacteria and are transported in an energy-consuming step into the periplasm. The 
required energy originates from the proton motive force across the bacterial inner membrane 
and is coupled to the siderophore receptor via the TonB system (Figure 1). The exact 
mechanism, how the energy is transduced to the outer membrane is not yet elucidated and 
several models are discussed. They include also periplasmic binding proteins, such as FhuD, 
which interacts with an inner membrane transporter, FhuBC, to carry the siderophore to the 
cytoplasm.[165,166] 
To counteract all iron acquisition systems of uropathogenic E. coli (UPEC) a whole-cell 
growth-based screen was performed using iron-limiting conditions, and a counterscreen under 
normal cultivation conditions. 16 out of a library of approximately 150.000 compounds were 
found to specifically inhibit UPEC under iron-limiting conditions with IC50 values in the 
range from 0.8±48 µM. Mode of action studies with loss of function mutants revealed that for 
at least 2 of these compounds probably the TonB±system is the target (86, 87, Figure 27).[166] 
Further studies of these compounds with respect to in vivo applicability are required, in 
particular as only 4 out of the 16 compounds were active on a wild-type strain and not only on 
the ǻ7RO&PXWDQWZKLFKODFNVWKHH[SRUWSXPS7RO&.  
 
Figure 27. Structures and inhibitory constants of the TonB inhibitors[166] and promysalin 88. 
Promysalin 88 (Figure 27), a salicylate-containing Pseudomonas putida antibiotic, promotes 
swarming and biofilm formation and selectively targets other Pseudomonas sp. including the 
opportunistic pathogen P. aeruginosa.[167] It disperses established biofilms and inhibits 
pyoverdine production.[168] At concentrations ranging from 6 to 100 mM it shows Fe3+ 
chelation properties, albeit with reduced affinity when compared to the known iron chelator 
EDTA. Thus, it was proposed that 88 inhibited siderophore transport pathways thereby 
VHYHUHO\OLPLWLQJRULQKLELWLQJWKHRUJDQLVP¶VDELOLW\WRDFTXLUHLURQHowever, the mechanism 
was not elucidated in detail. The total synthesis of promysalin 88 and a series of analogs and 
the evaluation of their antimicrobial activity have been recently reported.[168±171] 
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In Gram-positive bacteria, such as Staphylococcus aureus, transport systems for essential 
metal ions typically rely on substrate binding proteins (SBP) and an ABC transporter (Figure 
1). The Mn2+ uptake system comprising the SBP MntC and the membrane importer MntB is 
essential in S. aureus, as Mn2+ is a cofactor of enzymes involved in detoxification of reactive 
oxygen species. Until now no small molecule inhibitors of this pathway are described, but an 
antibody fragment was developed, which complexes MntC and prevents its interaction with 
MntB.[172] As a proof of concept it was shown that this antibody fragment (100 µg mL±1) 
reduced viable cell counts of S. aureus 12fold when exposed to reactive oxygen species. 
Thus, the potential of metal ion import systems as antibacterial targets may not yet be fully 
exploited. 
 
4. Iron Acquisition from Heme 
Heme is the most abundant iron species in the human body, but is present only 
intracellularly. Thus, heme uptake systems have evolved and are utilized by pathogens to 
various degrees depending on the type of the pathogen and the site of infection. Some Gram-
positive bacteria, such as Staphylococcus aureus[173] and Corynebacterium diphtheria, rely on 
heme uptake during pathogenesis, and also for P. aeruginosa the relevance during chronic 
lung infections of cystic fibrosis patients was shown.[174] A prerequisite for iron acquisition 
from heme is the secretion of hemolysins or cytolysins, usually proteins, which lead to lysis of 
host cells and thus to the release of intracellular proteins. As these mechanisms are best 
studied for S. aureus, the following description is focused on the heme uptake system of this 
pathogen. 
S. aureus produces several cytolysins, such as Į-toxin Į-hemolysin) Ȗ-toxin and bi-
component leucocidins, pore-forming toxins, which were shown to be relevant for the severity 
of diseases, such as pneumonia or sepsis.[175,176] The expression of these toxins and of the 
heme uptake system is induced by low iron concentrations via the Fur repressor, and further 
regulated by the activity of virulence-associated transcriptional regulators[177,178] so that they 
are only produced when needed. Lysis of host cells makes intracellular proteins, such as 
hemoglobin and other heme proteins, available to the pathogen, and S. aureus possess surface 
proteins providing capture of heme from hemoglobin and myoglobin, transportation through 
the membrane, and in the cytoplasm heme-degrading monooxygenases make Fe2+ available 
for bacterial processes.[179] 
Until now inhibitors of heme±LURQDFTXLVLWLRQWDUJHWWKHH[SUHVVLRQRUWKHDFWLYLW\RIĮ-toxin 
and some examples will be described in the following: 
Expression of the hemolysins is, together with the expression of other virulence factors, under 
the control of the accessory gene regulatory (agr) quorum sensing two-component system, in 
addition to the mgrA global transcriptional regulator and the Fur repressor. Due to their 
general relevance for virulence, screening campaigns for inhibitors of Agr and MgrA were 
performed.[180] The small molecule savarin 89 and mimetics of the quorum sensing 
compounds 25 decreased agr activity and significantly reduced the hemolytic activity of S. 
aureus. However, the therapeutic value is not unambiguous, as Agr-dysfunction has also been 
associated with persistent rather than resolving bacteremia, and mortality.[180] Reduced 
hemolytic activity and reduced virulence in a mouse model were also observed, when MgrA 
was inhibited directly or via phosphorylation by a serine±threonine phosphatase (stp1).[178] 
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Screening resulted in the identification of 5,5-methylenedisalicylic acid (90, MDSA) and the 
related compound aurintricarboxylic acid (91, ATA) (Figure 28) as inhibitors with activities 
in the µM range. 
Whereas these studies still await further exploitation, the activity of Į-hemolysin is inhibited 
by several small moleculeVDQGDOVRE\DPRQRFORQDODQWLERG\Į-Hemolysin is secreted by S. 
aureus as monomer. Contact of the protein to host cells leads to oligomerization and the 
formation of heptameric pores, a process which is favored by a protein receptor (ADAM10) 
EXW DOVR E\ OLSLG FRPSRQHQWV ȕ-Cyclodextrin derivatives 93 LQKLELWHG Į-hemolysin activity 
probably by blocking the pore and thus preventing loss of ions and small molecules from the 
cytosol.[181] A similar mechanism is suggested for the isatin-Schiff copper(II) complex 92 
(Figure 28).[182]  
 
Figure 28. Inhibitors of D-hemolysin expression (89±91) and of the permeability of the D-hemolysin pore (92, 
93). 
The phenolic and flavonoid inhibitors baicalin 94,[183] oroxylin A 96,[184] cyrtominetin 95[185] 
and curcumin 97[186] (Figure 29) are suspected to prevent assembly of the monomers to the 
heptamer. The most advanced agent, however, is the monoclonal antibody MEDI4893, which 
has proven efficacy in murine S. aureus pneumonia models, when used in a passive 
immunization strategy. This antibody is now evaluated in clinical studies.[187,188] 
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Figure 29. Phenolic and flavonoid inhibitors of the assembly RIĮ-hemolysin monomers to a functional pore. 
Inhibition of heme-iron acquisition systems of other bacteria have not yet gained as much 
interest as the system of S. aureus, though iron-regulated expression of hemolysin is also 
reported for other bacteria, such as Bacillus cereus, E. coli and Vibrio cholera.[189,190] Among 
the rare examples of inhibition of heme uptake is the structure-guided development of 
synthetic metal complexes, which replace heme in its binding site on the heme acquisition 
system A (HasA) protein. HasA is secreted by P. aeruginosa ELQGV KHPH ³OLNH D SDLU RI
WZHH]HUV´ DQG WUDQVIHUV WKH KHPH WR WKH KHPRSKRUH-specific outer membrane receptor 
HasR.[191] From the crystal structure of the heme-loaded HasA it was concluded that also 
other metal complexes could fit into the binding site, which was experimentally proven by 
ESI±TOF±MS. The Fe-phthalocyanine complex Fe-Pc completely inhibited growth of P. 
aeruginosa with a half-maximal inhibitory concentration of approximately 24 nM even in the 
presence of heme-bound HasAp.[191] 
5. Conclusion and Outlook 
As iron is essential for viability and growth of most organisms, sophisticated uptake 
systems have evolved in bacteria, which allow them to circumvent the limitations of low 
available iron concentrations imposed by an aerobic environment and by the additional 
withdrawal mechanisms of a vertebrate host. The relevance of the different uptake systems 
varies with bacterial species and with the particular conditions in the colonized niche. High 
affinity iron uptake systems are synthesized only on demand, i.e. bacteria regulate the 
expression of the respective proteins and the activity of enzymes in response to intracellular 
iron concentrations. In addition, the drop of the iron concentration is frequently taken as 
signal for the presence of host cells, leading to the expression of additional virulence factors.  
Thus, generally, bacterial iron uptake could be exploited for the treatment of infectious 
diseases by targeting a wide range of different proteins, resulting in decreased growth rates 
and virulence. However, a valuable target for one specific infectious disease may be useless 
for another. Moreover, the complexity of biological systems may lead to competition and 
interactions among different metal ions and thus, to side effects and loss of efficacy. Thus, the 
biological target and the inhibitory strategy have to be carefully chosen and a particular 
solution may be not applicable as broad-range therapy.  
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These may be the reasons why until now only some agents are the topic of in vivo or of 
even clinical studies. Animal models vary in their degree of clinical relevance depending on 
the animal, the infection route and the infection dose. For example, the infection of mice via a 
single dose of pathogens into the bloodstream will lead to a systemic infection, which may 
reflect the situation of sepsis, but this model is hardly indicative for infections of the gut, the 
lung or the skin. However, the relevance of specific iron uptake pathways may differ between 
infectious diseases as the available iron concentration and iron species differ between organs. 
Thus, application of inhibitors of a specific iron uptake pathway to a single animal model may 
not be sufficient to comprehensively evaluate the in vivo potency of the compound, which 
increases the efforts to obtain valid preclinical data.  
Thus, it is not surprising that until now mainly broad-spectrum reagents were evaluated in 
clinical studies: The siderophore ± cephalosporin conjugate (Trojan horse) S-649266 73 
(cefiderocol, Figure 22) from Shionogi & Co. Ltd (Japan) was applied to patients with 
complicated urinary tract infections (cUTI) with Gram-negative bacteria. Due to the success 
of the study cefiderocol 73 is eliglible for the fast-track approval status of the FDA. A phase 3 
study with patients carrying carbapenem-resistant Gram-negative bacteria is ongoing. Gallium 
citrate (PanaecinTM) from Aridis Pharmaceuticals is in a phase 2a clinical study, which enrolls 
cystis fibrosis (CF) patients who are chronically infected with Pseudomonas aeruginosa. Due 
to the broad antimicrobial activity of PanaecinTM an extension of the application range is 
expected. The development stage of the other ȕ-lactam antibiotic ± siderophore conjugates 
BAL 30072 71 (Basilea) and MC-1 72 (Pfizer) (Figure 22) is unclear, as they do not appear 
on the lists of antibiotics in clinical phases anymore. The in vitro development of resistant 
strains was reported for these two Trojan horse ± antibiotics, where reduced susceptibility 
correlated with increased expression of drug efflux pumps (BAL 30072) or siderophore 
receptors (MC-1 and MB-1). However, the resistance against MC-1 was not relevant in vivo, 
perhaps in vivo the loss of activity of a single receptor can be compensated by another one. 
Moreover, loss of activity of all siderophore receptors will also prevent the uptake of 
siderophores, which, however, is required for survival under iron-limiting conditions. As 
discussed above (Chap. 3.5.1) this may lead to fitness costs which may prevent the viability of 
resistant mutants in an infected host. The same is to be expected for PanaecinTM, as Ga3+-
loaded siderophores are taken up via the same pathways as Fe3+-loaded siderophores. Thus, 
any mutation, which leads to resistance due to inhibited uptake, will also lead to reduced 
uptake of the essential metal ion Fe3+ and thus, to reduced fitness and survival in the host. 
Whereas the present compounds in clinical phases are antibiotics, of which the uptake 
mechanism is optimized to prevent resistance development, the monoclonal antibody against 
Į-hemolysin of S. aureus does not target an essential bacterial protein but a virulence factor, 
which is active on host cells. As viability of S. aureus is not directly affected by the antibody, 
there is no selection pressure leading to resistant strains. On the other hand the risk of failure 
is high when the pathogen is able to use alternative toxins to get access to heme-iron. 
As discussed in this review the response of bacterial pathogens to metal ion stress in an 
infected host offers a wide range of very different targets, which could be the basis for novel 
anti-infective therapeutic approaches. The optimal future drug target may lead to the 
correlation between reduced susceptibility of strains to the drug and reduced viability in the 
infected host. However, compounds resulting from respective screening campaigns may be 
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only applicable to defined infections, which originate from a specific pathogen and affect a 
specific organ. This correlates to the trends of individualized medicine in other disease areas 
(e.g. cancer) and may lead to a more focused application of drugs thus preventing the rapid 
development of resistances, but requires additional efforts to establish suitable models which 
allow validation of the efficacy of lead compounds. 
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